Spero Therapeutics Inc (SPRO) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Spero Therapeutics Inc   (NASDAQ: SPRO)


Spero Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Spero Therapeutics Inc's ROI in the second quarter of 2026?
Spero Therapeutics Inc achieved a return on average invested assets (ROI) of 14.88 % in its second quarter of 2026, this is above SPRO's average return on investment of -59.7%.
Spero Therapeutics Inc invested over the 12 months ending in its second quarter of 2026 $50 million

ROI decreased relative to the period ending Mar 31 2026, due to the decline in net income.

Within the Healthcare sector 43 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 179 to 180.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -18.42 % -32.98 % -48.02 % -57.15 % -46.29 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 44 54 60 41 47
Return On Investment (TTM) 14.88 % 30.28 % 17.47 % -88.68 % -88.14 %
SPRO's Overall Ranking # 180 # 179 # 347 # 3798 # 3258
Seq. Investment Change TTM -1.41 % 2.54 % -0.72 % -18.72 % -19 %
Seq. Net Income Change TTM -51.54 % 77.73 % - - -
Net Income (TTM) in Millions 7 15 9 -44 -54

SPRO Company Profile >> Back to SPRO Roi Comparisons >> See Annual SPRO Return On Investment



Return On Investment SPRO's Ranking
Within: No.
Industry # 15
Sector # 44
Overall # 180

Return On Investment Statistics
High Average Low
29.73 %
-59.7 %
-638.92 %
(Mar 31 2026)   (Mar 31 2018)







Financial Statements
Spero Therapeutics Inc's II. Quarter Investments $ 44 Millions SPRO's Balance sheet
Spero Therapeutics Inc's II. Quarter Income $ -10 Millions Quarterly SPRO's Income Statement
SPRO's Income by Division See SPRO's Income by Division


SPRO Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 59 61 145 98 119
Y / Y Investment Growth -3.83 % -57.68 % 47.91 % -17.41 % -10.07 %
Net Income in Millions 9 -69 23 -46 -90
Y / Y Net Income Growth - - - - -
Annual Return On Investment 14.5 % -111.55 % 15.7 % -47.27 % -75.49 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 14.5 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SPRO's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SPRO's Competitors
Subscribers only: Roi for Spero Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for SPRO's Customers

Other Ratios
SPRO's Roa SPRO's Inventory Turnover Ratio SPRO's Growth Rates SPRO's Dividend Statistics
SPRO's Profitability Ratios SPRO's Asset Turnover Ratio SPRO's Dividend Growth
SPRO's Roe SPRO's Valuation Ratios SPRO's Financial Strength Ratios SPRO's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %
Neurocrine Biosciences Inc   17.51 %

Date modified: 2026-09-26T07:32:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.